Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions.
Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions.
复制标题
DOI：
10.1177/1932296816631569
复制
发表时间：
2016-09-01
影响因子：
5
通讯作者：
Jacobs, Peter G
中科院分区：
文献类型：
--
作者：
Castle, Jessica R;Jacobs, Peter G
虽然自我血糖监测 (SMBG) 是糖尿病患者管理血糖水平的现行标准，但最近连续血糖监测 (CGM) 技术准确性的提高使得糖尿病相关的治疗决策很可能很快将仅根据 CGM 值做出。 CGM 的非辅助使用将导致患者管理血糖水平的方式发生转变，并且需要护理人员教育患者、监测患者进展并提供反馈以帮助他们管理糖尿病的方式发生重大改变。批准使用 CGM 非辅助治疗也是 FDA 批准人工胰腺系统的关键一步，该系统有望进一步改变 1 型糖尿病患者的糖尿病护理。在本文中，我们讨论非辅助 CGM 预计将如何很快取代常规 SMBG，以及这种新的使用场景预计将如何改变健康结果和患者护理。
While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.